At two-year fol­low-up, Evrys­di con­tin­ues to show nu­mer­i­cal im­prove­ments in da­ta, Roche says

A lit­tle less than two months af­ter re­ceiv­ing an FDA ap­proval in spinal mus­cu­lar at­ro­phy, Roche’s Genen­tech con­tin­ues to roll out da­ta for ris­diplam.

The drug, mar­ket­ed as Evrys­di in the US, showed im­proved mo­tor func­tions in in­fants as part of a two-year fol­low-up eval­u­a­tion from Part 1 of a piv­otal tri­al on which its ap­proval is based. Nu­mer­i­cal­ly, there were more pa­tients who could sit with­out sup­port for five sec­onds, main­tain up­right head con­trol, turn them­selves over and stand than those at one year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER